Ribociclib plus hormone therapy extends survival for patients with premenopausal advanced hormone receptorpositive breast cancer

Ribociclib plus hormone therapy extends survival for patients with premenopausal advanced hormone receptor-positive breast cancer

(University of Texas M. D. Anderson Cancer Center) Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

More From BioPortfolio on "Ribociclib plus hormone therapy extends survival for patients with premenopausal advanced hormone receptor-positive breast cancer"